Core Viewpoint - Recently, Kexing Pharmaceutical and Auscan Biopharmaceutical Co., Ltd. have established a strategic partnership to jointly develop the KXBS001 biosimilar, marking their entry into the European and American biosimilar markets [1] Group 1: Strategic Partnership - Kexing Pharmaceutical has formed a strategic collaboration with Auscan Biopharmaceutical to develop biosimilars [1] - The partnership aims to leverage both companies' strengths to accelerate the research and development process of the KXBS001 biosimilar [1] Group 2: Market Opportunities - The European Medicines Agency (EMA) has recently announced a draft plan to simplify the review process for biosimilars, potentially providing a "fast track" for domestic pharmaceutical companies to enter the EU market [1] - According to an IQVIA report, the EU accounts for approximately 40% of the global biosimilar market value [1] Group 3: Company Strategies - Kexing Pharmaceutical adheres to an "innovation + internationalization" strategy and has developed a comprehensive antibody technology platform with capabilities across various therapeutic areas, including antiviral, oncology, and autoimmune diseases [1] - Auscan Biopharmaceutical's chairman highlighted Kexing's rapid progress in internationalization and expressed confidence in leveraging cutting-edge technology to enhance the collaboration [1] - Kexing's chairman noted that Auscan's team possesses extensive experience in CMC development and commercialization in the large molecule field, indicating a strong foundation for future collaboration [1]

Group 1 - Junsheng Electronics' subsidiary has recently secured a global automotive intelligence project with a total order value of approximately 15 billion yuan, expected to start mass production in 2027 [2] - Purun Co. is planning to acquire controlling stakes in Noah Changtian Storage Technology Co., which will enhance its market competitiveness and operational scale [3] - Longpan Technology's subsidiary has signed a procurement cooperation agreement with CATL, with an estimated total sales amount exceeding 6 billion yuan for lithium iron phosphate cathode materials from 2026 to 2031 [4] Group 2 - Shanghai Construction's gold business revenue is relatively low, accounting for less than 0.5% of total revenue, and recent reports about increased gold reserves are based on previously disclosed information [5][6] - Yinglian Co. plans to raise up to 1.5 billion yuan through a private placement to enhance its business layout and service capabilities [8] - Aoyang Health's major shareholder is transferring 20% of its shares, which will change the controlling shareholder to Yuesheng Technology [10]

Group 1 - Beijing Junzheng announced that shareholder Beijing Yitang Shengxin reduced its stake by 4.8254 million shares, accounting for 0.999999% of the total shares, without affecting control or ongoing operations [1] - Zhongtai Automobile is required to pay Shanghai Sizhi 29.5 million yuan and overdue interest due to a court ruling on an intellectual property dispute, which may significantly impact current or future performance [2] - Borui Pharmaceutical received approval to conduct clinical trials for BGM0504 tablets in overweight/obese adults, with no similar oral formulations approved globally [2] - Kexing Pharmaceutical's preliminary transfer price for shares is set at 30.88 yuan per share, representing a 28% discount from the closing price [2] Group 2 - Nanfeng Co. announced that its subsidiary's 3D printing service project has not yet been implemented, and it is still in the early stages, with no significant impact on current revenue or profits [3] - Dingtong Technology plans to invest up to 15 million USD to establish a wholly-owned subsidiary in Vietnam for the development and production of various connectors and cooling products [4] - Xindazheng is planning to acquire at least 51% of Jiaxin Liheng Facility Management, leading to a significant asset restructuring, with stock suspension effective from September 15, 2025 [5] - Junsheng Electronics' subsidiary has received a global automotive intelligence project worth approximately 15 billion yuan, with production expected to start in 2027 [6][7] - Green's Harmonics reported that shareholders Zuo Jing and Zuo Yuyue have completed a total reduction of 2.99% of shares [8] - Shoukai Co. reported significant stock trading activity, including a notable increase in shareholder numbers and some institutional shareholders reducing their stakes [9] Group 3 - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [10] - Huachao City A experienced a 57% decrease in contract sales amounting to 990 million yuan in August [10] - Hongrun Construction won a bid for a 126 million yuan project related to Shanghai Metro Line 21 [10] - Shuangxin Electronics plans to acquire 88.79% of Ligon Technology for 700 million yuan [10] - Jingtai Semiconductor intends to acquire 100% of Chip Micro Semiconductor for 316 million yuan [10] - Huada Gene's preliminary transfer price is set at 44.10 yuan per share [10] - Huahai Qingke's transfer price is set at 102 yuan per share [10] - Jingke Energy's transfer price is set at 4.90 yuan per share [10] - Hangke Technology's actual controller plans to transfer 3% of total shares [10] - Landai Technology received approval for a control change from the Anhui State-owned Assets Supervision and Administration Commission [10] - *ST Yuanshang's controlling shareholder plans to transfer 5.1% of shares to Xinda Assets [10] - Quanzhu Co. reported that shareholder Wang Jianjun plans to transfer 68.5 million shares to Qingdao Xinhui Investment [10] Group 4 - Lizhong Group received a project designation for aluminum alloy wheels worth an estimated 5.8 billion yuan [11] - Longci Technology plans to invest 210 million yuan in the second phase of its Vietnam project for localized supply of permanent magnet ferrite raw materials [11] - Laofengxiang's subsidiary plans to jointly invest in a modern refining plant and testing laboratory [11] - Zhongding Co. has core technology in humanoid robots and has signed strategic cooperation agreements with multiple companies [11] - Silek signed a 230 million yuan investment cooperation agreement for precision structural components in the new energy sector [11] - Bai Ao Intelligent plans to invest 3 million USD to establish a wholly-owned subsidiary in Vietnam for AI-related products [11]

Group 1 - Junsheng Electronics' subsidiary recently secured project notifications from two leading automotive manufacturers, with a total order value of approximately RMB 15 billion, expected to start mass production in 2027 [1] - The project will involve the development and provision of a range of automotive intelligent products, including CCU and intelligent networking [1] Group 2 - Borui Pharmaceutical's subsidiary received approval to conduct clinical trials for BGM0504 tablets in overweight/obese adults, marking the first approval for an oral formulation targeting the same receptors globally [2] - BGM0504 is a dual agonist of GLP-1 and GIP receptors, aimed at controlling blood sugar, weight loss, and treating non-alcoholic fatty liver disease (NASH) [2] Group 3 - Jingchen Co. plans to acquire 100% equity of Chip Micro Semiconductor for a total consideration of RMB 316 million, enhancing its capabilities in IoT, automotive networking, and mobile smart terminals [3] - The acquisition aims to build a multi-dimensional communication technology stack and product matrix, focusing on AIoT solutions [3] Group 4 - Dingtong Technology intends to invest up to USD 15 million to establish a wholly-owned subsidiary in Vietnam for the R&D and production of high-speed communication connectors and liquid cooling heat sinks [4] Group 5 - Xinda Zheng is planning to acquire at least 51% of Jiaxin Liheng Facility Management, with the transaction expected to constitute a major asset restructuring [5] Group 6 - Sinovac Biotech announced a preliminary transfer price of RMB 30.88 per share for a block of shares, representing a 28% discount to the closing price of RMB 42.81 [6] - The transfer has been fully subscribed by 21 institutional investors, with a total of 10.19 million shares effectively subscribed [6] Group 7 - Zhongtai Automobile was ordered to pay RMB 29.5 million plus overdue interest due to a court ruling related to an intellectual property dispute, which may significantly impact its current and future performance [7] Group 8 - Beijing Junzheng's shareholder reduced holdings by 482,540 shares, accounting for approximately 0.999999% of the company's total shares, without affecting control or ongoing operations [8][9] Group 9 - Green's Harmonic reported that its co-controlling shareholders completed a total reduction of 2.99% of shares, with specific reductions of 274,510 shares by one shareholder and 274,080 shares by another [10] Group 10 - Shangluo Electronics plans to raise up to RMB 1 billion through convertible bonds to acquire 88.79% of Ligon Technology, which specializes in the distribution of various IC products [11]

Company Announcements - Junsheng Electronics' subsidiary has recently secured a global automotive intelligence project with a total order value of approximately 15 billion yuan, expected to start mass production in 2027 [1] - Shangluo Electronics plans to acquire 88.79% of Ligon Technology for 700 million yuan, focusing on authorized distribution of storage chips and various IC products [2][3] - Xinda Zheng intends to purchase at least 51% of Jiaxin Liheng Facility Management (Shanghai) Co., Ltd., with the stock currently suspended [1] - Dingtong Technology plans to invest up to 15 million USD to establish a wholly-owned subsidiary in Vietnam for R&D and production of optical module liquid cooling products [1][3] - Kexing Pharmaceutical's shareholders are inquiring about transferring shares at an initial price of 30.88 yuan per share, which is a 28% discount compared to the closing price [4] - Zhongtai Automobile has been ordered to pay 29.5 million yuan plus overdue interest due to a court ruling, which may significantly impact its current or future performance [5] - Shoukai Co., Ltd. has seen a significant increase in shareholder numbers and some institutional shareholders have reduced their holdings [5] Investment and Contracts - Laofengxiang plans to jointly invest in establishing Laofengxiang Precision Materials Company to build a modern refining and testing laboratory [8] - Longci Technology intends to invest 210 million yuan in the second phase of its Vietnam project to localize the supply of permanent magnet ferrite raw materials [9] - Sileck has signed a 230 million yuan investment cooperation agreement for a new energy precision structural components project [10] Shareholding Changes - Jingchen Co. plans to acquire 316 million yuan for 100% of Chip Micro Semiconductor [6] - Beijing Junzheng has seen a reduction of 4.8254 million shares by its shareholder Beijing Yitang Shengxin [5] - Green Harmony's actual controllers have completed a reduction of 2.99% of their shares [7] - Hangke Technology's actual controller plans to transfer 3% of the total share capital [7] Stock Price Movements - Nanfeng Co. has reported that its 3D printing service project has not yet materialized, which may affect its current year's revenue and profit [3] Other Developments - Borui Pharmaceutical's BGM0504 tablets have been approved for clinical trials in overweight/obese adults, with no similar oral formulations approved globally [4] - Southwest Securities' subsidiary will lose its listing status on September 29 due to failure to meet resumption guidelines [20]

Suspension - New Dazheng is planning to issue shares and pay cash to acquire no less than 51% equity of Jiaxin Liheng Facility Management (Shanghai) Co., Ltd., and is raising matching funds, resulting in stock suspension [1] Mergers and Acquisitions - Jingchen Co., Ltd. intends to acquire 100% equity of Chipmike Semiconductor for a total consideration of 316 million yuan [2] - Shangluo Electronics plans to acquire 88.79% equity of Ligon Technology, a distributor of IC products, for 700 million yuan [3] Share Buybacks and Equity Transfers - Canrui Technology plans to repurchase shares for 20 million to 40 million yuan, with a maximum repurchase price of 52.46 yuan per share [4] - Kejie Intelligent is adjusting its maximum repurchase price from 15.77 yuan per share to 23.73 yuan per share [4] - Xindian Software's chairman proposed a share repurchase of 30 million to 50 million yuan [4] - Industrial Fulian is repurchasing and canceling 1.2855 million restricted stock options [5] - Kexing Pharmaceutical's shareholder inquiry transfer is preliminarily priced at 30.88 yuan per share, representing a 28% discount from today's closing price [6] - Hangke Technology's actual controller, Cao Ji, plans to transfer 3% of the total share capital through inquiry [7] External Investments and Daily Operations - Junsheng Electronics' subsidiary has recently secured a global automotive intelligence project worth approximately 15 billion yuan, with production planned to start in 2027 [8] - Sileck has signed an investment cooperation agreement for a 230 million yuan new energy precision structural components project [9] - Longmag Technology's wholly-owned subsidiary in Vietnam plans to invest approximately 210 million yuan to construct a second-phase project, adding 10,000 tons of permanent magnet ferrite wet-pressed magnetic tile capacity and supporting 25,000 tons of pre-burned material capacity [9] - Kangtai Biological's Sabin strain inactivated polio vaccine (Vero cells) has been approved for market launch [10] - Zhongding Co., Ltd. possesses core technology in humanoid robots and has signed strategic cooperation agreements with multiple enterprises [11] - Dingtong Technology plans to invest 15 million USD to establish a wholly-owned subsidiary in Vietnam for the research and production of optical module liquid cooling radiators [12] - Borui Pharmaceutical's BGM0504 tablets have been approved for clinical trials in overweight/obese adult patients, with no similar oral formulations approved globally [12] - Longmag Technology plans to invest 210 million yuan in the second phase of its Vietnam project to achieve localized supply of permanent magnet ferrite raw materials [13]

Group 1 - Yihau New Materials plans to reduce its shareholding by up to 1% of the company's total shares, amounting to 165,500 shares, due to personal funding needs [1] - Fuxing Pharmaceutical's subsidiary has received approval for a new indication for its drug, which is used in the treatment of certain types of breast cancer [1][2] - Shantui Co. has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [3] Group 2 - Sierte's chairman plans to increase his shareholding by an amount between 3 million to 6 million yuan [4] - Borui Pharmaceutical's BGM0504 tablet has received approval for clinical trials in overweight and obese adults [5] - Ganyue Expressway reported vehicle toll service revenue of 349 million yuan for August [6] Group 3 - Chip Microelectronics has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [7] - Lingrui Pharmaceutical's director plans to reduce his shareholding by up to 200,000 shares, representing 0.0353% of the total shares [8] - Jiahu Energy has adjusted its share repurchase price limit to 11.63 yuan per share [10] Group 4 - Spring Airlines reported a year-on-year increase of 12.23% in passenger turnover for August [11] - Kaida has received an invention patent for a self-calibrating sensor technology [12] - Chuanheng Co. has obtained a new utility model patent aimed at improving industrial waste utilization [14] Group 5 - Huashi Technology received a government subsidy of 2.21 million yuan, accounting for 22.71% of its latest audited net profit [15] - Shanghai Pharmaceuticals' controlling shareholder plans to increase its H-share holdings by up to 74 million shares [16] - Hongrun Construction has won a bid for a significant segment of the Shanghai Metro Line 21 project, valued at 126 million yuan [18] Group 6 - Sanfangxiang plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on green technology [19] - Lao Fengxiang's subsidiaries plan to jointly invest in luxury goods sales and gold refining companies [20][21] - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [22] Group 7 - Inner Mongolia First Machinery has signed a railway freight car procurement contract worth 186 million yuan [22] - Jiuqiang Bio has received five invention patents related to diagnostic reagents [24] - Longmag Technology plans to invest 210 million yuan in its second phase project in Vietnam [25] Group 8 - Galaxy Magnetics plans to acquire 100% equity of Kyoto Longtai, with its stock suspended for trading [26] - Jinlong Co.'s controlling shareholder will have 30 million shares auctioned [27] - Haishi Co.'s controlling shareholder has released the pledge on 29.97 million shares [28] Group 9 - Qiu Tianwei plans to reduce its shareholding by up to 1.17% of the total shares [29] - Xiaocheng Technology's directors plan to reduce their shareholding by a total of 0.08% [30] - Victory Co. reported that Sunshine Life Insurance has reduced its shareholding by 4.4 million shares [31] Group 10 - Xindong Technology plans to distribute a cash dividend of 0.156 yuan per share [32] - Huaqin Technology plans to distribute a cash dividend of 0.13 yuan per share [33] - Kexing Pharmaceutical's controlling shareholder intends to transfer 5% of the company's shares [35] Group 11 - Guojin Securities has completed the repayment of its second short-term financing bond for 1.0205 billion yuan [38] - Chunhui Intelligent Control's application for asset acquisition has been accepted by the Shenzhen Stock Exchange [39] - Chaohongji has submitted its H-share issuance application to the Hong Kong Stock Exchange [40] Group 12 - Tianyue Advanced has fully exercised its over-allotment option, involving 716,180 H-shares [40] - Chengfeng Technology's vice president has resigned due to internal adjustments [41] - Yingpais plans to establish a 100 million yuan technology sports industry investment fund [43]

受让方通过询价转让受让的股份，在受让后 6 个月内不得转让。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 30.88 元/股。 （二）参与本次询价转让报价及申购的机构投资者家数为 21 家，涵盖了基 金管理公司、证券公司、合格境外机构投资者、私募基金管理人等专业机构投资 者。参与本次询价转让报价及申购的机构投资者合计有效认购股份数量为 10,190,000 股，对应的有效认购倍数为 1.01 倍。 证券代码：688136 证券简称：科兴制药 公告编号：2025-076 科兴生物制药股份有限公司 股东询价转让定价情况提示性公告 股东深圳科益医药控股有限公司（以下简称"出让方"）保证向科兴生物制 药股份有限公司（以下简称"公司"）提供的信息内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据 2025 年 9 月 15 日询价申购情况，初步确定的本次询价转让价格为 30.88 元/股。 1 经营。 特此公告。 科兴生物制药股份有限公司董事会 2025 ...

Core Insights - The animal vaccine sector saw a rise of 1.30%, ranking 9th among concept sectors, with 14 stocks increasing in value, led by TianKang Biological, BioShares, and Jinhe Biological, which rose by 8.20%, 7.17%, and 3.00% respectively [1][2] - The sector experienced a net inflow of 190 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow, led by Hengtong Co. with 71.08 million yuan [2][3] Sector Performance - The animal vaccine sector's performance was highlighted by the following stocks: - Hengtong Co.: 2.41% increase, 4.20% turnover rate, 71.08 million yuan net inflow, 15.05% net inflow ratio - Jinhe Biological: 3.00% increase, 5.44% turnover rate, 30.31 million yuan net inflow, 10.35% net inflow ratio - Kanghua Biological: 2.14% increase, 4.54% turnover rate, 44.90 million yuan net inflow, 10.14% net inflow ratio [3][4] Stock Movements - The top gainers in the animal vaccine sector included: - TianKang Biological: 8.20% increase - BioShares: 7.17% increase - The stocks with the largest declines included: - Shenlian Biological: 1.51% decrease - Dongfang Biological: 1.31% decrease - Xianfeng Holdings: 1.24% decrease [1][4]

Core Viewpoint - The initial pricing for the share transfer of Kexing Pharmaceutical is set at 30.88 CNY per share, representing a 28% discount compared to the closing price of 42.81 CNY per share on the same day [1] Group 1 - Kexing Pharmaceutical announced that the initial pricing for the share transfer is 30.88 CNY per share based on the inquiry subscription situation as of September 15, 2025 [1] - A total of 21 institutional investors participated in the bidding and subscription, with a combined effective subscription quantity of 10.19 million shares, resulting in an effective subscription multiple of 1.01 times [1] - The total number of shares to be transferred is 10.06 million shares, which has been fully subscribed by the 21 institutional investors [1]